Undegraded human immunoglobulin for intravenous use.
A report is presented on the development and the properties of a nondegraded human immunoglobulin preparation suitable for intravenous administration. Intravenous tolerance is achieved by elimination of anticomplementary activity through modification with beta-propiolactone. The natural antibody characteristics, such as antibody activity, molecular weight, and half-life, are retained. The findings presented open up new perspectives for an extension of the range of indication for intravenous immunoglobulin.
D000327:Adsorption; D000937:Antigen-Antibody Reactions; D001666:Binding Sites, Antibody; D003168:Complement Fixation Tests; D003165:Complement System Proteins; D006207:Half-Life; D006385:Hemagglutination Inhibition Tests; D005779:Immunodiffusion; D007122:Immunoelectrophoresis; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007136:Immunoglobulins / Q000008:administration & dosage*; D007275:Injections, Intravenous; D008970:Molecular Weight; D011309:Preservation, Biological; D011420:Propiolactone / Q000494:pharmacology; D014461:Ultracentrifugation
D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D011420:Propiolactone; D003165:Complement System Proteins